Marinomed Biotech AG · VIE:MARI
Marinomed Biotech — Fact Sheet (November 2023)
13 slides from Marinomed Biotech's fact sheet, November 2023
Slide 1: Carragelose eye drops for lubrication and beyond
Carragelose eye drops for lubrication and beyond November 2023
Slide 2: Disclaimer
Disclaimer These materials (the “Presentation”) have been provided to you by Marinomed Biotech AG together with its respective members, directors, officers, employees, advisers or agents (together “Marinomed”) in connection with a potential transaction relating to Marinomed’s asset Carragelose eye d
Slide 3: Executive summary: Carragelose eye drops
Executive summary: Carragelose eye drops Lubricant eye drops to treat DED with a potential in viral keratoconjunctivitis Business model Market opportunity Clinically proven Carragelose® • Ophthalmic partner in • Tapping into fast • Clinical studies with a • Sulfated polymer classical license deal Pa
Slide 4: Licensing opportunities - overview
Licensing opportunities - overview 2 product licenses available 1. Carragelose Dry Eye Relief 2. Carragelose Antiviral Eye Drops Description • Sterile, preservative free ophthalmic solution in • Sterile, preservative free ophthalmic a multi dose container solution in a multi dose container • Unique
Slide 5: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in the Vienna region 2006 2008 2016 2019 2021 2022 Foundation Launch of Carragelose Invention of IPO and Marinosolv Marinosolv deal and Deal with Marinosolv clinical validation Solv4U launch Procter & Gamble Therapeutic areas VI
Slide 6: Pipeline
Pipeline Including late-stage projects with low risk and high upside potential © Marinomed Biotech AG 6
Slide 7: Carragelose: Protective layer against viruses and allergens
Carragelose® CCA2 market volume: Protective layer against viruses and allergens – multi-use potential US$ 36 bn3 Viral respiratory diseases Carragelose Eye care • Broadly-active against numerous • Carragelose has excellent respiratory viruses moisturizing and mucoadhesive properties • Clinically val
Slide 8: Carragelose mode of action and benefits
Carragelose® mode of action and benefits Mode of action1 • Carragelose non-specifically covers the mucosal surface and prevents binding of virus/allergen to the mucosa, thereby reducing the immune response without being pharmacologically active • Carragelose is mucoadhesive and lubricating Without i
Slide 9: Carragelose beyond Virus and Allergens
Carragelose® beyond Virus and Allergens Excellent hydrating and mucoadhesive properties • Carragelose is iota-carrageenan derived from red seaweed in pharmaceutical quality • Carragelose is a new opportunity to treat dry eye disease • Carragelose has the potential to be the first product targeting a
Slide 10: Carragelose as eye lubricant
Carragelose® as eye lubricant A high molecular weight polymer with moisturizing and mucoadhesive properties • High molecular weight polymers, such as Carragelose, do not penetrate mucosa or skin • Carragelose is known for an exceptionally high water uptake1 and excellent water retention properties2.
Slide 11: Carragelose eye drops: Eyeleen
Carragelose eye drops Eyeleen Product characteristics: • Regulatory status: medical device class IIa (EU, MDD), application for MDR (IIb) by end of 2023; valid CE mark under transition period until 2028 (MDD) • Legal manufacturer: Hälsa Pharma GmbH, Lübeck (MDR certified) • Notified body: Medcert Lü
Slide 12: Carragelose – Broadly active virus blocker
Carragelose® – Broadly active virus blocker These viruses infect the respiratory tract or the eye and may worsen diseases such as COPD or keratoconjunctivitis In-vitro In-vivo Virus type Clinical data data data Corona virus (OC43, 229E) SARS-CoV-2 Rhinovirus A and B Influenza A virus: hu
Slide 13: www.marinomed.com www.carragelose.com
www.marinomed.com www.carragelose.com Contact: [email protected]